Atomoxetine and cerebrovascular outcomes in adults

Journal of Clinical Psychopharmacology

Volumn 29, Issue 5, 2009, Pages 453-460

  Holick, Crystal N ^a,c   Turnbull, Bruce R ^a   Jones, Meghan E ^b   Chaudhry, Saadia ^a   Bangs, Mark E ^b   Seeger, John D ^a  

^a i3 Drug Safety   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c HEALTHCORE INC   (United States)

Author keywords

Adults; Atomoxetine; Cerebrovascular disease; Propensity scores; Stimulant

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; NARCOTIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; WARFARIN;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROPYLAMINES; RISK FACTORS; STROKE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349678243     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181b2b828     Document Type: Article

References (27)

1. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64:205-222.
2. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit- hyperactivity disorder. N Engl J Med. 1999;340: 780-788.
3. Zametkin AJ, Ernst M. Problems in the management of attention-deficit- hyperactivity disorder. N Engl J Med. 1999;340: 40-46.
4. Eli Lilly and Company Strattera. Strattera medication guide. Available at: http://pi.lilly.com/us/strattera-ppi.pdf. Accessed October 14, 2008.
5. Eli Lilly and Company. Clinical trials registry. Strattera clinical trial results. Available at: http://www.lillytrials.com/results/by-product/results
6. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003; 26:729-740.
7. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/ hyperactivity disorder: an interim analysis. J Clin Psychiatry. 2005;66:294-299.
8. Adler LA, Spencer TJ,Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with attention-deficit/ hyperactivity disorder: final report of a 4-year study. J Atten Disord. 2008;12(3):248-253.
9. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59:829-835.
10. Weisler RH, Biederman J, Spencer TJ, et al. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10:35-43.
11. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005;66: 253-259.
12. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920.
13. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333.
14. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
15. Rosenbaum PR, Rubin DB. The central roles of the propensity score in observational studies for causal effects. Biometrika. 1988;70:41-55.
16. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc; 2001:214-226.
17. Adams H Jr, del Zoppo G, von Kummer R. Management of Stroke: A Practical Guide for the Prevention, Evaluation, and Treatment of Acute Stroke. 2nd ed.West Islip, NY: Professional Communications Inc; 2002.
18. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723.
19. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil. 1998;31:533-544.
20. Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics. 2005;23:93-102.
21. Ferro JM, Falcao I, Rodrigues G, et al. Diagnosis of transient ischemic attack by the nonneurologist. A validation study. Stroke. 1996;27:2225-2229.
22. Kraaijeveld CL, van Gijn J, Schouten HJ, et al. Interobserver agreement for the diagnosis of transient ischemic attacks. Stroke. 1984;15: 723-725.
23. Dennis MS, Bamford JM, Sandercock PA, et al. Incidence of transient ischemic attacks in Oxfordshire, England. Stroke. 1989;20:333-339.
24. Lemesle M, Madinier G, Menassa M, et al. Incidence of transient ischemic attacks in Dijon, France. A 5-year community-based study. Neuroepidemiology. 1998;17:74-79.
25. Sempere AP, Duarte J, Cabezas C, et al. Incidence of transient ischemic attacks and minor ischemic strokes in Segovia, Spain. Stroke. 1996; 27:667-671.
26. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav. 2001;68:611-627.
27. Iso H, Jacobs DR Jr, Goldman L. Accuracy of death certificate diagnosis of intracranial hemorrhage and nonhemorrhagic stroke. The Minnesota Heart Survey. Am J Epidemiol. 1990;132:993-998.